… virus.2 Treatment with antivirals like tenofovir and entecavir can … and treatment, and to break the silence around hepatitis B. … better testing, and expanded treatment, are essential to reduce … not received treatment. The WHO's 2016 hepatitis elimination …

… Phase 2 trial of hydronidone for the treatment of chronic hepatitis B (CHB … ), double-blind, placebo-controlled, multicenter, entecavir-based Phase 3 clinical study … antifibrotic indication for this novel drug. Reference: Cai X, Qu Y …

… tenofovir and entecavir for managing chronic Hepatitis B. While these treatments do not … trial landscape is expanding, with the Asia-Pacific leading 65% of trials … Frost & Sullivan 2024 Global Biotech CRO Award and the 2024 …

… treatments remains low. Transmitted via bodily fluids, symptoms of hepatitis … trial conducted in partnership with American biotech … drug regulator National Medical Products Administration (NMPA) in November 2023. Phase 2 trials … Pharmaceuticals’ drug …

… fibrosis among patients with chronic hepatitis B (CHB). The study, conducted … were randomized to receive daily entecavir plus either placebo or hydronidone … approved drugs specifically indicated for the treatment of liver fibrosis, this trial could …

… Phase 2 trial of hydronidone for the treatment of chronic hepatitis B (CHB … ), double-blind, placebo-controlled, multicenter, entecavir-based Phase 3 clinical study … antifibrotic indication for this novel drug. Source: Journal reference: Cai, X …

… , retrospective study was conducted. The medical records of 12144 adult (≥18 … data rather than prospective clinical trials, which may have introduced biases … carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir …

… for patients with CHB undergoing treatment with entecavir (ETV) or tenofovir … ; (3) Patients with autoimmune hepatitis, drug-induced liver injury, alcoholic liver … , Medical Association. The guideline of prevention and treatment for chronic hepatitis B …

… biotech sponsors.   What are the biggest challenges in running Hepatitis B trials … FDA, EMA, PMDA, and NMPA requirements, ensuring compliance across trial … )ide analogues, Entecavir and Tenofovir, … medicine in Hepatitis B treatment is transforming clinical trial …

… innovative, commercial-stage biotechnology company with clinical … Hepatitis B: Protocol for a Phase 3 Randomized Trial … in addition to entecavir antiviral basic therapy … Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments …